• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
Real-time monitoring of respiratory virus-associated hospitalizations: Trends through early October 2024

Real-time monitoring of respiratory virus-associated hospitalizations: Trends through early October 2024

by Truveta staff | Oct 28, 2024 | Research

Overall, the rate of hospitalizations associated with respiratory viruses decreased throughout September 2024 and into the first week of October. For infants and children aged 0-4 years old, respiratory virus-associated hospitalizations increased slightly by 2.9%...
Advancing orthopedics: How device-level data is shaping the future of knee, hip, and shoulder replacements

Advancing orthopedics: How device-level data is shaping the future of knee, hip, and shoulder replacements

by Truveta staff | Oct 10, 2024 | Data

The US market size for joint replacement is projected to balloon to nearly $38 billion by 2030, nearly doubling its 2022 value. The combination of an aging population, increasing rates of osteoarthritis and obesity, along with advancing technology, are all...
Truveta recognized on national and Seattle LinkedIn Top Startup 2024 lists

Truveta recognized on national and Seattle LinkedIn Top Startup 2024 lists

by Truveta News | Oct 9, 2024 | News

Today, Truveta was featured as #3 on LinkedIn’s inaugural Top Startups in Seattle list. The ranking highlights ten growing start-up companies in the Seattle area.   Last month, Truveta was also included on the national LinkedIn’s Top Startups list for 2024, which...
Case study: De-risking clinical development and driving therapeutic innovation in heart failure

Case study: De-risking clinical development and driving therapeutic innovation in heart failure

by Truveta staff | Sep 26, 2024 | Technology

Despite advances in guideline-directed medical therapy, heart failure (HF) readmission rates have worsened over the past decade. Optimizing acute inpatient decongestion is critical in mitigating HF morbidity and mortality, but few new treatment strategies have emerged...
Real-time monitoring of respiratory virus-associated hospitalizations: Trends from October 2019 through August 2024

Real-time monitoring of respiratory virus-associated hospitalizations: Trends from October 2019 through August 2024

by Truveta staff | Sep 19, 2024 | Research

Overall, the rate of hospitalizations associated with respiratory viruses remained stable throughout August 2024, with no change compared to July 2024. For infants and children aged 0-4 years old, respiratory virus-associated hospitalizations increased significantly...
« Older Entries
Next Entries »

Share this


Recent posts

  • Truveta leads a new era in cancer research with the most complete, representative, and timely real-world data on all cancers
  • Top 5 takeaways from Truveta Symposium 2025
  • Women’s health: Pain medication remains rare for women receiving IUDs

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Get started

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Interested in learning more?

Our website uses cookies to ensure you have the best experience.AcceptPrivacy notice